Faricimab (Vabysmo) is a bispecific antibody against angiopoietin‐2 and VEGF‐A for the treatment of adults with wet age‐related macular degeneration (AMD) and visual impairment due to diabetic macular oedema. This article discusses its administration, clinical trial outcomes and place in therapy.
{"title":"Faricimab for treating wet AMD and diabetic macular oedema","authors":"S. Chaplin","doi":"10.1002/psb.2026","DOIUrl":"https://doi.org/10.1002/psb.2026","url":null,"abstract":"Faricimab (Vabysmo) is a bispecific antibody against angiopoietin‐2 and VEGF‐A for the treatment of adults with wet age‐related macular degeneration (AMD) and visual impairment due to diabetic macular oedema. This article discusses its administration, clinical trial outcomes and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88595503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.
{"title":"Emerging roles of sodium‐glucose co‐transporter inhibitors","authors":"A. Barton","doi":"10.1002/psb.2014","DOIUrl":"https://doi.org/10.1002/psb.2014","url":null,"abstract":"Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"99 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86091449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NICE recently updated its guideline on the management of depression in adults (NG222). This article summarises the new guidance, which includes detailed recommendations on treatment options for new episodes of depression, preventing relapse, further‐line therapy, and managing chronic depressive symptoms.
{"title":"Updated guideline on managing depression in adults","authors":"S. Chaplin","doi":"10.1002/psb.2017","DOIUrl":"https://doi.org/10.1002/psb.2017","url":null,"abstract":"NICE recently updated its guideline on the management of depression in adults (NG222). This article summarises the new guidance, which includes detailed recommendations on treatment options for new episodes of depression, preventing relapse, further‐line therapy, and managing chronic depressive symptoms.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88469676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Healthcare professionals’ documentation of adverse drug reactions is sometimes suboptimal, but it is important to take time to detail the nature of these reactions and their timing and severity to ensure patients’ safety and trust in the healthcare system.
{"title":"Upping our game when documenting adverse reactions","authors":"A. Thompson","doi":"10.1002/psb.2020","DOIUrl":"https://doi.org/10.1002/psb.2020","url":null,"abstract":"Healthcare professionals’ documentation of adverse drug reactions is sometimes suboptimal, but it is important to take time to detail the nature of these reactions and their timing and severity to ensure patients’ safety and trust in the healthcare system.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"292 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77300088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cenobamate (Ontozry) is a new antiseizure medicine for the adjunctive treatment of focal‐onset seizures with or without secondary generalisation in patients with drug‐resistant epilepsy. This article summarises its properties and place in therapy.
{"title":"Cenobamate for focal‐onset seizures in resistant epilepsy","authors":"S. Chaplin","doi":"10.1002/psb.2018","DOIUrl":"https://doi.org/10.1002/psb.2018","url":null,"abstract":"Cenobamate (Ontozry) is a new antiseizure medicine for the adjunctive treatment of focal‐onset seizures with or without secondary generalisation in patients with drug‐resistant epilepsy. This article summarises its properties and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"153 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75317048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ponesimod (Ponvory) is a new sphingosine 1‐phosphate receptor modulator for the treatment of adults with relapsing forms of multiple sclerosis (MS). This article discusses its mode of action, efficacy and adverse effects.
{"title":"Ponesimod for the treatment of relapsing multiple sclerosis","authors":"S. Chaplin","doi":"10.1002/psb.2019","DOIUrl":"https://doi.org/10.1002/psb.2019","url":null,"abstract":"Ponesimod (Ponvory) is a new sphingosine 1‐phosphate receptor modulator for the treatment of adults with relapsing forms of multiple sclerosis (MS). This article discusses its mode of action, efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"95 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87955575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neurological diseases: optimism for the future","authors":"","doi":"10.1002/psb.2013","DOIUrl":"https://doi.org/10.1002/psb.2013","url":null,"abstract":"","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74030121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Discriminating ‘self’ from ‘non‐self’ and avoiding autoimmune disease is a fine balancing act for the immune system. Recent research has increased our understanding of the underlying mechanisms that throw immunity off balance, raising the prospect of improved management and earlier diagnosis of autoimmune conditions.
{"title":"Autoimmune diseases: the immunological tightrope","authors":"M. Greener","doi":"10.1002/psb.2016","DOIUrl":"https://doi.org/10.1002/psb.2016","url":null,"abstract":"Discriminating ‘self’ from ‘non‐self’ and avoiding autoimmune disease is a fine balancing act for the immune system. Recent research has increased our understanding of the underlying mechanisms that throw immunity off balance, raising the prospect of improved management and earlier diagnosis of autoimmune conditions.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87303904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：